Tanshinone IIA attenuates the inflammatory response and apoptosis after traumatic injury of the spinal cord in adult rats.
BACKGROUND
Spinal cord injury (SCI), including immediate mechanical injury and secondary injury, is associated with the inflammatory response, apoptosis and oxidative stress in response to traumatic injury. Tanshinone IIA (TIIA) is one of the major extracts obtained from Salvia miltiorrhiza BUNGE, which has anti-inflammatory and anti-apoptotic effects on many diseases. However, little is known about the effects of TIIA treatment on SCI. Therefore, the aim of the present study is to evaluate the pharmacological action of TIIA on secondary damage and the underlying mechanisms of experimental SCI in rats.


RESULTS
SCI was generated using a weight drop device on the dorsal spinal cord via a two-level T9-T11 laminectomy. SCI in rats resulted in severe trauma, characterized by locomotor disturbance, edema, neutrophil infiltration, the production of astrocytes and inflammatory mediators, apoptosis and oxidative stress. TIIA treatment (20 mg/kg, i.p.) after SCI induced significant effects: (1) improved motor function (Basso, Beattie and Bresnahan scores), (2) reduced the degree of tissue injury (histological score), neutrophil infiltration (myeloperoxidase activity) and the expression of astrocytes, (3) inhibited the activation of SCI-related pathways, such as NF-κB and MAPK signaling pathways, (4) decreased the production of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and iNOS, (5) reduced apoptosis (TUNEL staining, and Bcl-2 and caspase-3 expression) and (6) reversed the redox state imbalance.


CONCLUSIONS
The results clearly show that TIIA has a prominent protective effect against SCI through inhibiting the inflammatory response and apoptosis in the spinal cord tissue after SCI.
Institute of Orhopaedics Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China.
Xin
X
Yin
Yue
Y
Yin
Fa-Le
FL
Cao
Yu-Fei
YF
Chen
Ye
Y
Peng
Wu-Gang
WG
Hou
Shu-Kai
SK
Sun
Zhuo-Jing
ZJ
Luo
D045784:Abietanes / Q000494:pharmacology / Q000627:therapeutic use*; D000375:Aging / Q000187:drug effects / Q000473:pathology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001253:Astrocytes / Q000187:drug effects / Q000473:pathology; D015415:Biomarkers / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D007249:Inflammation / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D018836:Inflammation Mediators / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D020556:Neutrophil Infiltration / Q000187:drug effects; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects; D013116:Spinal Cord / Q000187:drug effects / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology; D013119:Spinal Cord Injuries / Q000150:complications / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D014947:Wounds and Injuries / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D045784:Abietanes; D015415:Biomarkers; D016207:Cytokines; D018836:Inflammation Mediators; D016328:NF-kappa B; C021751:tanshinone; D052247:Nitric Oxide Synthase Type II